Mapping oligogenes for atopy and asthma by meta-analysis

A. Collins, S. Ennis, W. Tapper and N.E. Morton

Abstract

Meta-analysis is presented for published studies on linkage or allelic association that have in common only reported significance levels. Reporting is biased, and nonsignificance is seldom quantified. Therefore meta-analysis cannot identify oligogenes within a candidate region nor establish their significance, but it defines candidate regions well. Applied to a database on atopy and asthma, candidate regions are identified on chromosomes 6, 5, 16, 11, 12, 14, 7, 20, and 10, in rank order from strongest to weakest evidence. On the other hand, there is little support for chromosomes 9, 8, 18, 1, and 15 in the same rank order. The evidence from 156 publications is reviewed for each region. With reasonable type I and II errors several thousand affected sib pairs would be required to detect a locus accounting for 1/10 of the genetic effect on asthma. Identification of regions by a genome scan for linkage and allelic association requires international collaborative studies to reach the necessary sample size, using lod-based methods that specify a weakly parametric alternative hypothesis and can be combined over studies that differ in ascertainment, phenotypes, and markers. This has become the central problem in complex inheritance.

INTRODUCTION

Current interest in complex inheritance is motivated by the positional cloning paradigm that seeks to map an oligogene affecting disease susceptibility as a prelude to cloning, sequencing, functional studies and potential medical application. The chromosome region that is scanned may be the whole genome or a candidate suggested by function or by preliminary evidence from linkage or allelic association. Published studies are rarely decisive for moderate effects and never have high power for small effects. Consequently the literature provides numerous samples for a particular chromosome region, differing in phenotype definition, population, genetic markers, selection of probands and relatives, and statistical methods. The common denominator is a significance level assigned by large-sample theory or simulation, perhaps one-tailed or with a Bonferroni correction for the number of tests performed. Few investigators realise that estimation of location introduces an extra degree of freedom that affects significance levels which, although peer-reviewed, are subject to many ambiguities, errors and biases. However, apart from functional and cytogenetic studies they are presently the only basis for mapping in the absence of costly collaborations that discard much of the evidence and are opposed by a competitive tradition now reinforced by industrial secrecy. Here we develop a theory for meta-analysis of published studies, apply it to a database on atopy and asthma, and define candidate regions.

MATERIAL AND METHODS

Ideally evidence from each study on multiple markers in a particular candidate region would be summarised by a multipoint lod evaluated at the location of each marker, conditional on genetic parameters (Lio and Morton, 1997). However, this is impossible for nonparametric methods and impractical for a fully parametric model, which cannot represent complex inheritance accurately. Weakly parametric methods summarise relations between genotypes and phenotypes by a parsimonious model in which frequencies and penetrances are confounded without distorting the effect of recombination (Morton and Collins, 1998). These models are variously parametrised, of uncertain relative efficiency, not yet in general use, and so are more appropriate for collaborative studies that adopt the same genetic map, although not necessarily the same phenotypes or markers. We therefore consider evidence from a single marker that may be summarised by a nominal significance level $P$ with $\chi^2_2 = -2 \ln P$ and corresponding $\chi^2_1$, from which the lod if the sample gives evidence against the null hypothesis is $z = \chi^2_1/(2 \ln 10)$. Some studies report $\chi^2_{2,1}$, which may be transformed through $P$ to $z$ (Morton, 1998). There are several ways to estimate $P$ for the NPL statistic in GENEHUNTER, and the results may be strikingly different (e.g. Hizawa et al., 1998). A variant computes a one-tailed $P$ value by simulation and converts $2P$ to a lod as above, but a nominal $\chi^2_1$ is more usual and more likely to be conservative than other approximations. With other computer programs we accept
the published P value, which may not consider the number of tests and so the evidence is less reliable for allelic association than for linkage. A report of “nonsignificant” with no further specification is assigned \( z = 0 \), which is the minimum value for the MLS and similar statistics (Holmans, 1993; Kruglyak and Lander, 1995). Lods give evidence against the alternative hypothesis by taking negative values. Truncation to nonnegative values is a patent bias that could be avoided if valid lods were reported instead of significance levels, \( \chi^2 \), MLS, or other statistics that obscure evidence against the alternative hypothesis.

When significance tests for a particular marker in a given study were reported for several correlated traits, we accepted at most one asthma phenotype and one atopy phenotype. A global trait like asthma score was preferred to a component trait like bronchial response. In the absence of a global trait we averaged lods over component traits. A few studies included eosinophils, which we considered separately but grouped with asthma for comparison with atopy.

For analysis samples falling into a bin of \( i \pm 0.5 \) cM on the sex-average map (where \( i \) is an integer) are attributed to the included marker with the most samples. Hereafter only markers with at least one lod greater than zero are considered. Given \( n \) nominally independent lods \( z_1, ..., z_n \) for a particular marker, \( (2 \ln 10) \sum_i^N z_i \) is taken as \( \chi^2 \) and transformed to a summary lod \( Z \). The maximum \( Z \) in a region is denoted \( Z_m \). Heterogeneity among samples within the marker is tested as \( \chi^2 = (2 \ln 10) Z. \) Treating the \( N \) markers in a region as independent, \( \chi^2_{N_1} = (2 \ln 10) \sum_{i=1}^N Z \) with corresponding lod \( Z_{N_1} \). Heterogeneity among markers is tested as \( \chi^2 = (2 \ln 10) Z \) with corresponding lod \( Z_{N} \).

To identify candidate regions we select \( Z \) in descending order, but not within 40 cM of a marker already selected, using the currently best sex-average genetic coordinates in the location database LDB (Collins et al., 1996a), and continue until the largest remaining \( Z \) is less than 1. Let the ordered set of selected locations for a given chromosome be \( c_1, ..., c_r \), where \( c_1 \) is closest to pter, the telomere of the short arm. Each of the \( r \) candidate regions is bounded by the midpoint of the intervals to the next selected marker or (at ends) by the telomere. Some candidate regions will contain more than one disease locus and therefore be partitioned as evidence accumulates. Conversely adjacent candidate regions may be merged or the boundary shifted. The human genome is divided by this procedure into fewer than 100 potential regions. Although unlikely to reach conventional significance levels by chance, one or more may appear significant through biased reporting of positive results (Morton, 1998).

A limitation of mapping methods based only on significance levels is that we must assume wrongly that each of \( n \) samples within the \( j \)th marker has equal information. Then for all \( N \) markers within a region with \( \chi^2 > 0 \) the composite likelihood is assumed to follow the Malecot equation (Collins and Morton, 1998), \( \ln L = -\sum_j (\chi_j^2 - C - (1-C)) \chi^2/n_j/d_j = \delta (S_j - \hat{S}) \), and \( \delta = 1 \) if \( S_j \geq \hat{S} \) or -1 else. Here \( S_j \) is the location of the \( j \)th marker and \( \hat{S} \) is the location of the disease gene estimated by maximum likelihood. The nuisance parameters describe the maximum in a region (A), the decline of linkage or allelic association with distance (B), and the bias (C) due to exclusion of nonsignificant reports that are represented in the data by \( \chi^2 = 0 \). Usually linkage and allelic association are pooled within and among loci, and then a single value of \( B \) is estimated for each region. The residual \( \chi^2 \) for a region is estimated with \( N-q \) degrees of freedom, where \( q \) is the number of parameters estimated. The corresponding error variance, assumed independent of region, is \( V = \sum \chi^2 / \sum (N - q) \), where summation is over all regions.

We considered 4 subhypotheses of the Malecot model:

1. \( A = B = 0 \) (q = 1)

2. \( A, B \) | \( C = 0.321 \) (q = 3, V = 0.82)

3. \( C \) | \( A = B = 0 \) (q = 1)

4. \( A = B = 0 \), \( C = 0.321 \) (q = 0)

where 0.321 was the mean of \( \hat{C} \) over the 29 regions under the first subhypothesis. Then if the corresponding value of -2 ln L for a given region under \( V = 1 \) is \( \chi^2 \) (i = 1, ..., 4), there are three tests of the Malecot model:

\[
(y_4 - y_2)/V, \text{ d.f.} = 3 \rightarrow Z_1
\]
\[
(y_4 - y_1)/V, \text{ d.f.} = 4 \rightarrow Z_2
\]
\[
(y_3 - y_1)/V, \text{ d.f.} = 3 \rightarrow Z_3
\]

Each of these \( Z \) values is associated with 1 d.f. (like \( Z_m, Z_{N_1}, Z_{N} \), defined above) and in large-sample theory may be multiplied by 2 ln 10 to give a chi-square under a specific pair of hypotheses. \( Z_1 \) tests the hypothesis that \( A = B = 0 \) when \( C \) is constant among regions. \( Z_2 \) tests the hypothesis that \( C \) is constant among regions and \( A = B = 0 \). \( Z_3 \) tests the hypothesis that \( A = B = 0 \) when each region has its own value of \( C \). These tests have different sensitivity to variations in \( C \) and to the shape of one or more peaks. For example, \( Z_3 \) has low power to detect peaks extending over most of the region.

There have been frequent attempts to summarise evi-
Mapping oligogenes for atopy and asthma
dence on complex inheritance without a database (e.g., Duffy, 1997; Perusse et al., 1997). Internet gives a general asthma database (http://cooke.gsf.de). We used a specialised database ASTHMALOD for significance levels reported by marker locus. At the end of 1998 it contained records from 156 publications on 518 loci, of which 446 had at least one nonzero lod. There were 403 marker bins. A computer program LITDAT updates genetic and physical locations and performs the above analysis (http://cedar.genetics.soton.ac.uk/public_html/).

RESULTS

Data on all the autosomes have been reported, and for most of them there is at least one locus suggestive of linkage. Lods testing different aspects of the data are positively correlated and may be summarised by the rank of the first principal component of the correlation matrix. Table I presents evidence on the autosomes in rank order.  

Table I - Chromosomes and candidate regions.

<table>
<thead>
<tr>
<th>Chromosome and region</th>
<th>Marker</th>
<th>Z_m</th>
<th>Z_r</th>
<th>Z_n</th>
<th>Malecot</th>
<th>Z ≥ 3</th>
<th>Z ≥ 2</th>
<th>Malecot</th>
<th>Functional candidates</th>
<th>P.C. rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 all</td>
<td>HLA-DRB1</td>
<td>41.00</td>
<td>50.00</td>
<td>6.82</td>
<td>50.25</td>
<td>52.58</td>
<td>23.17</td>
<td>5 6 11 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 all</td>
<td>IL4</td>
<td>14.27</td>
<td>44.16</td>
<td>7.96</td>
<td>41.19</td>
<td>42.70</td>
<td>9.06</td>
<td>6 7 16 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 proximal</td>
<td>IL4RA</td>
<td>23.35</td>
<td>25.07</td>
<td>3.05</td>
<td>22.04</td>
<td>24.22</td>
<td>12.56</td>
<td>2 2 4 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 all</td>
<td>FCE11B</td>
<td>17.07</td>
<td>18.33</td>
<td>4.40</td>
<td>17.96</td>
<td>18.25</td>
<td>6.14</td>
<td>2 3 10 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 proximal</td>
<td>D12S351</td>
<td>2.62</td>
<td>12.72</td>
<td>4.08</td>
<td>14.10</td>
<td>14.29</td>
<td>1.32</td>
<td>1 3 9 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 all</td>
<td>D13S153</td>
<td>5.06</td>
<td>8.26</td>
<td>2.11</td>
<td>4.45</td>
<td>5.81</td>
<td>2.10</td>
<td>2 3 0 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 distal</td>
<td>PI</td>
<td>6.64</td>
<td>9.20</td>
<td>1.92</td>
<td>5.03</td>
<td>4.86</td>
<td>0.36</td>
<td>2 3 2 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 distal</td>
<td>D7S684</td>
<td>5.97</td>
<td>6.71</td>
<td>2.15</td>
<td>4.68</td>
<td>5.46</td>
<td>2.66</td>
<td>1 2 4 8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 distal</td>
<td>D16S289</td>
<td>3.02</td>
<td>4.00</td>
<td>1.99</td>
<td>5.33</td>
<td>5.87</td>
<td>0.70</td>
<td>1 2 0 9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 all</td>
<td>CD40</td>
<td>3.00</td>
<td>2.65</td>
<td>1.13</td>
<td>3.77</td>
<td>3.79</td>
<td>2.99</td>
<td>1 2 1 10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 proximal</td>
<td>D14S50</td>
<td>3.11</td>
<td>4.94</td>
<td>1.29</td>
<td>3.24</td>
<td>3.21</td>
<td>0.35</td>
<td>1 1 1 11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 proximal</td>
<td>D7S2550</td>
<td>4.35</td>
<td>3.10</td>
<td>0.74</td>
<td>2.56</td>
<td>2.46</td>
<td>2.66</td>
<td>1 1 3 12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 medial</td>
<td>D14S63</td>
<td>3.88</td>
<td>2.79</td>
<td>1.16</td>
<td>2.11</td>
<td>2.10</td>
<td>1.18</td>
<td>1 1 2 13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 all</td>
<td>D10S190</td>
<td>3.66</td>
<td>0.52</td>
<td>2.47</td>
<td>2.57</td>
<td>2.47</td>
<td>2.89</td>
<td>1 1 6 14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19 proximal</td>
<td>C3</td>
<td>2.52</td>
<td>3.14</td>
<td>0.99</td>
<td>2.17</td>
<td>2.67</td>
<td>0.75</td>
<td>0 1 7 15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21 all</td>
<td>D21S1262</td>
<td>2.28</td>
<td>1.52</td>
<td>0.76</td>
<td>2.14</td>
<td>2.05</td>
<td>2.09</td>
<td>0 1 3 16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 distal</td>
<td>D12S342</td>
<td>2.26</td>
<td>2.54</td>
<td>0.95</td>
<td>1.95</td>
<td>1.87</td>
<td>1.27</td>
<td>0 1 1 17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 all</td>
<td>D4S426</td>
<td>2.63</td>
<td>0.47</td>
<td>0.40</td>
<td>2.16</td>
<td>1.96</td>
<td>2.33</td>
<td>0 1 7 18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 proximal</td>
<td>D3S1263</td>
<td>2.35</td>
<td>1.08</td>
<td>0.63</td>
<td>1.33</td>
<td>1.11</td>
<td>1.34</td>
<td>0 1 2 19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22 all</td>
<td>IL2RB</td>
<td>2.10</td>
<td>0.94</td>
<td>0.53</td>
<td>0.76</td>
<td>0.62</td>
<td>0.67</td>
<td>0 1 5 20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 all</td>
<td>D2S834</td>
<td>1.36</td>
<td>0.22</td>
<td>0.23</td>
<td>1.59</td>
<td>1.36</td>
<td>1.24</td>
<td>0 0 15 21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17 all</td>
<td>DCP1</td>
<td>1.12</td>
<td>1.11</td>
<td>0.73</td>
<td>0.93</td>
<td>0.96</td>
<td>0.26</td>
<td>0 0 12 22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19 proximal</td>
<td>D19S178</td>
<td>1.75</td>
<td>0.90</td>
<td>0.56</td>
<td>0.78</td>
<td>0.61</td>
<td>0.24</td>
<td>0 0 2 23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 distal</td>
<td>D3S1300</td>
<td>1.80</td>
<td>0.20</td>
<td>0.21</td>
<td>0.86</td>
<td>0.75</td>
<td>1.01</td>
<td>0 0 3 24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 all</td>
<td>D9S925</td>
<td>1.78</td>
<td>0.06</td>
<td>0.08</td>
<td>0.55</td>
<td>0.77</td>
<td>0.97</td>
<td>0 0 5 25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 all</td>
<td>LPL</td>
<td>1.02</td>
<td>0.01</td>
<td>0.01</td>
<td>0.27</td>
<td>0.18</td>
<td>0.31</td>
<td>0 0 1 26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18 all</td>
<td>SLC14A1</td>
<td>1.03</td>
<td>0.00</td>
<td>0.01</td>
<td>0.00</td>
<td>0.00</td>
<td>0.01</td>
<td>0 0 0 27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 all</td>
<td>D1S1669</td>
<td>0.47</td>
<td>0.00</td>
<td>0.00</td>
<td>0.09</td>
<td>0.04</td>
<td>0.08</td>
<td>0 0 19 28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 all</td>
<td>D15S153</td>
<td>0.27</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.02</td>
<td>0 0 0 29</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Strong candidate chromosomes

Chromosome 6

The HLA region in chromosome 6 gives a strong signal by all lods. Most of the evidence comes from the HLA-DRB1 marker with atopy (33 reports), but the 5 asthma reports are nominally significant and concordant (Z = 5.42, homogeneity χ² = 2.94). Many of the results deal with specific IgE or responses to specific allergens. Some of these are unusual, such as aspirin atopy and asthma produced by soybeans or isocyanate. Within the HLA-DRB1 bin are a few reports on closely linked markers in the HLA region. One study reported strong evidence for association

Z₁, Z₂, and Z₃ are all good predictors of the first principal component (r > 0.99), but the number of functional candidates is a poor predictor (r = 0.57). Chromosome 13 with no known functional candidates has strong evidence for at least one candidate region, whereas chromosomes 1 and 2 with many functional candidates have little evidence for a candidate region. Chromosomes 5, 6, 7, 11, 12, 13, 14, and 16 have at least one candidate region that appears to be well supported. Evidence for more than one region is strongest for chromosomes 7, 12, 14, and 16 (Figure 1).
Figure 1 - Candidate chromosomes. Maximal lods location in cM from pter. End of chromosome indicated by arrowhead.
Mapping oligogenes for atopy and asthma

of HLADQB1 with aspirin allergy, but no association with HLADRB1 (Kowalski et al., 1997). It is likely that more than one class II locus affects specific allergen response, to which the asthma association is secondary. On the contrary, the TNF region is primarily associated with inflammation. The closely linked and partially homologous markers TNF and LTA are binned with D6S1019, and all 8 reports are on asthma (Z = 3.97). TNF may be homologous with Bhr3, a locus for bronchial hyperreactivity in the mouse (De Sanctis et al., 1995). Two reports on the PAFAH2 locus for platelet activating factor distal to the HLA region suggest association of severe asthma with a low activity allele (Miwa et al., 1988; Stafforini et al., 1996; Z = 2.76). Proximal to the HLA region the bin for D6S1281 which includes D6S276 gives evidence of linkage to eosinophilia (Daniels et al., 1996; Z = 3.29), dominating the pooled evidence from 6 samples (Z = 3.88). Heterogeneity between the unreplicated eosinophilia report and the residual within the bin is significant (\(\chi^2_1 = 4.60\)) suggesting that the candidate locus, if not a type I error, may predispose more to eosinophilia than to asthma or atopy.

Chromosome 5

Significant linkage and association have been reported at multiple loci with some suggestion of different specificities. IL4 gives evidence of linkage and association to noncognate IgE (Marsh et al., 1994; Dzierz et al., 1999). A locus for familial eosinophilia maps to D5S816 (Rioux et al., 1998), and this is supported by a sample of discordant
sib pairs (Martinez et al., 1998). ADRB2 is associated with asthma and bronchial reactivity (D’Amato et al., 1998). IL12B shows linkage with atopy in the mouse (Gorham et al., 1996), but not in the human (Meyers et al., 1994). It would not be surprising if there were more than one candidate locus in the cytokine region.

**Chromosome 16**

Our algorithm divides this chromosome into a proximal region with candidates MEFV and IL4R, and a distal region in which two microsatellites have suggestive lods. Mutations in MEFV cause Mediterranean fever, an autosomal recessive disease commonly treated with colchicine. This drug is anti-inflammatory, and therefore likely to suppress asthma to some extent. However, in one report patients before diagnosis had a significantly lower frequency of atopy than controls (Ozyilkik et al., 1994). Whether or not MEFV homozygotes are at reduced risk for asthma, there is no evidence that heterozygotes are protected, and so MEFV is unlikely to play a significant role in asthma even in populations where Mediterranean fever is common. The interleukin-4 receptor (IL4R), closely linked to an integrin cluster, is a stronger candidate for both atopy and asthma. Association with the Q576R polymorphism in IL4R has been reported (Yandava et al., 1998), but other studies are negative (Howard et al., 1998). In the distal region there is suggestive linkage of IgG to D16S265 (Wiltshire et al., 1998) and of IgE to D16S289 (Daniels et al., 1996), but no functional candidates.

**Chromosome 11**

The FCER1B locus gives significant evidence of linkage and association, primarily but not exclusively with measures of atopy, but its effect has been controversial (Thomas and Holgate, 1998). Several studies have suggested no linkage or association with paternal alleles. The only mechanism known to produce an allele-specific “parent-of-origin” effect is imprinting. This has not been reported for FCER1B in mice or humans, but nonexpression of paternal alleles at some critical stage of a particular tissue cannot be excluded. Some studies have not observed different risks in maternal and paternal transmission. There are several candidate loci in this region, and Adra et al. (1998) suggested that asthma susceptibility is determined by a locus distal to FCER1B.

**Chromosome 12**

This chromosome, divided into two regions, shows a broad peak that is therefore only weakly positive by \( Z_1 \), but appears highly significant by other tests in the proximal region. The evidence comes from both asthma and atopy, whereas the distal region, including D12S342, is primarily supported by evidence from asthma (Wilkinson et al., 1998). Although there are several candidates, none is strongly supported by allelic association.

**Chromosome 13**

The algorithm assigns the whole chromosome to one strongly supported region for which there are no functional candidates. Although two distinct peaks 30 cM apart are supported by measures of atopy and serum immunoglobulin levels, there is no intervening evidence (Wiltshire et al., 1998).

**Chromosome 14**

This is the only chromosome divided by our approach into three regions. The first includes D14S50, the alpha chain of the T-cell receptor TCRA and mast cell chymase 1, close to the leukotriene b4 receptor LTB4R. The medial region includes D14S63, where the evidence comes entirely from atopy (Mansur et al., 1999). The distal region includes the alpha-1-protease inhibitor PI in which the Z and S alleles are associated with asthma (Townley et al., 1990), and the IGH loci with some atopy-associated alleles (Oxelius et al., 1998). In the future this region will probably be divided.

**Chromosome 7**

In the proximal region D7S2250 (binned with D7S484) gives evidence of linkage to atopy, asthma, and eosinophilia (Daniels et al., 1996). Distally there is a higher peak around D7S684 that includes the cystic fibrosis transmembrane conductance regulator CFTR (Dahl et al., 1998) and the beta chain of the T cell receptor TCRB (Noguchi et al., 1998).

**Suggestive candidate chromosomes**

The X chromosome is underreported, and conventional tests of sex linkage are not appropriate for the pseudautosomal regions. A recent abstract suggests linkage with IL9R in the small pseudoautosomal region on the long arm (Holroyd et al., 1998). If the tests were one-tailed the nominal significance level corresponds to a multipoint lod of 3.23 for asthma by GENEHUNTER, but a smaller lod by two other methods. The GENEHUNTER NPL score is 2.98, corresponding to a lod of 1.93 by the normal approximation.

Eight autosomes present evidence that is no more than suggestive. **Chromosome 20** gives a lod of 2.07 for association of asthma to the 1-1 genotype at the adenosine deaminase locus ADA (Ronchetti et al., 1984), close to the tumour necrosis factor receptor INFRSF5 (formerly called CD40). A locus Bhr1 for bronchial hyperresponsiveness has been assigned to the homologous region in the mouse (De Sanctis et al., 1995). **Chromosome 10** gives
a lod of 3.66 for linkage of IgA levels to D10S190 (Wiltshire et al., 1998), but other immunoglobulin levels are nonsignificant. Chromosome 19 has suggestive lods at C3 (Srivastava et al., 1985) and D19S178, which is binned with the anti-inflammatory locus TGFB1 (Marsh et al., 1997; Hobbs et al., 1998). Chromosome 21 has a peak lod of 2.28 for BHR at D21S1262, close to IFNAR2 and IFNGR2 (Ober et al., 1997). Asthma is not significant. Residual \( \chi^2 \) is significant (P = 0.002), reflecting scores of 1.12 and 0.68 for asthma with D21S156 and D21S1440 about 11 cM distally, near ITGB2 (Marsh et al., 1997).

On chromosome 4 a genome scan gives a lod of 2.63 for BHR with D4S426, near IRF2 (Daniels et al., 1996). In a second panel linkage of D4S426 is suggestive for IgE and atopy in maternal meiosis, but not in paternal transmission. Bronchial response was not measured. Most of the evidence favouring linkage to chromosome 3 comes from a genome scan that included measurements of serum IgA, IgM, and IgG (Wiltshire et al., 1998). The D3S1263 marker near IL5RA gives a suggestive lod of 2.35 for IgG. At a distance of about 44 cM the D3S1300 marker gives a lod of 1.80 for IgA. Assessment of correlated phenotypes is difficult, and the authors concluded that “the marginal significance levels of the results ... require that these regions be investigated further to establish whether they are genuine linkages”. Adra et al. (1998) reported a lod of 1.35 for association between BCL6 HindIII genotypes and RAST scores, but not total or specific IgE levels.

Weak candidate chromosomes

Nearly all the data for chromosomes 1, 2 and 15 come from a single study that reported its nonsignificant findings (Marsh et al., 1997). The main exception is a lod of 1.48 for association of asthma with a promoter polymorphism in IL10 on chromosome 1 (Hobbs et al., 1998). On chromosome 17 an insertion-deletion polymorphism in the angiotensin-converting enzyme locus is associated with ACE levels, and therefore is a candidate gene for asthma (Benessiano et al., 1997). In a case-control study the DD homozygote was associated with asthma. This lod of 1.12 is weak, but there is a functional rationale. Residual \( \chi^2 \) for chromosome 17 when this evidence is removed is barely significant (P = 0.04). The next largest lod of 0.83 is for the eotoxin locus SCYA11 (Lilly et al., 1997), at which the Ala27Thr homozygote is elevated in asthmatics. A functional effect of this allele is not known, but the authors note that “its position in the eotoxin sequence implies that it may alter the rate of eotoxin secretion.” The chromosome 9 marker D9S925 in Hutterites gives a significance level for linkage to asthma that corresponds to a lod of 2.87, and weaker evidence for association with an unspecified number of alleles. BHR was tested but not reported (Ober et al., 1997). Other CSGA data are negative, reducing the lod to 1.78. The chromosome 8 evidence for linkage to asthma is not supported by atopy and was considered by its authors to be not confirmed (Brereton et al., 1994). The chromosome 18 marker SLC14A1 is the JK blood group, reported for suggestive linkage to serum IgE levels in males only (Eiberg et al., 1985). From published results it seems unlikely that these weak candidate chromosomes harbour an important determinant of atopy or asthma. However, a larger sample, a different phenotype score, a more powerful ascertainment scheme, or an unrelated population might well reveal oligogenes of low frequency or small effect.

DISCUSSION

Atopy and asthma illustrate all the problems that complex inheritance poses to genetics, statistics, and medicine. Recurrence risks estimate the logarithm of odds (\( \beta \)) as 1.06 for asthma and 0.49 for hay fever (Collins et al., 1996b). Assuming that family environment makes no contribution to \( \beta \), that genetic effects are additive on this scale, and that hay fever is a good surrogate for atopy, a locus that accounts for 1/10 of the genetic effect would have a \( \beta \) value of about 0.1 for asthma and 0.05 for atopy. A sequential linkage test with reasonable type I and II errors would require about 2000 affected sib pairs in the first case and 8000 in the second (Morton, 1996). A fixed sample size test with the same errors would need samples about three times as large (Morton, 1955). None of the national consortia approaches such sample sizes. Either international collaboration must be undertaken, or linkage abandoned in favour of allelic association with Bonferroni correction and controversial expected sample size, or the positional cloning paradigm will fail for most oligogenes.

This pilot study of meta-analysis helps to define candidate regions for positional cloning, but statistical significance of such biased and variable reports is in doubt. Exclusion mapping is not feasible when small effects are reported only as nonsignificant. The good performance of the regional lod \( Z_r \), which takes loci within a region as independent, may not extend to multilocus studies at higher resolution. \( Z_r \), which becomes less conservative as the bias represented by C diminishes, might be the statistic of choice if significance levels were reported for “nonsignificant” results. Consensus on statistical methods would be helpful, but unlikely to be critical unless the evidence from each study is reduced to a standard lod table that can incorporate negative as well as positive values. This approach was the key to genetic mapping of major loci, becoming redundant only when regional assignment is so secure that emphasis shifts from hypothesis testing to estimation of location (Morton, 1955, 1995). Complex inheritance introduces the locus effect \( \beta \) or variance component V as a nuisance parameter and is parametrised in terms of genetic location S rather than recombination \( \theta \), which is not directly observed because only marker genotypes are known. When efficient lods are in general use, meta-analysis and collaboration will be formally equivalent. This synthesis
will challenge variance component and other methods that assume random sampling and a continuous phenotype. Constraints on lods that prohibit negative values such as the "possible triangle" of MLS (Holmans, 1993) invalidate summation of lods and weighted estimates of parameters. Valid methods specify an alternative hypothesis and give negative lods in regions where an excess of nonidentity by descent makes the estimated effect negative.

There is no consensus among genetic epidemiologists about optimal meta-analysis or its presentation. Gu et al. (1998) advocated the mean identity by descent (IBD) at a specified locus to combine extremely concordant and extremely discordant sib-pairs for dichotomous and quantitative traits. Unlike lod-based methods, this approach to meta-analysis does not allow for more typical sib pairs, relatives other than sibs, allelic association, uncertainty about the number of alleles IBD or use of variance component models.

Recent evidence suggests that some candidate loci affect susceptibility to several inflammatory diseases, including asthma, inflammatory bowel disease, and rheumatoid arthritis, while other loci are disease-specific (Becker et al., 1998; Zhang et al., 1999; Satsangi et al., 1999). Meta-analysis provides a way to test heterogeneity among diseases within a candidate region and to pool evidence on location where appropriate. We are currently extending ASTHMALOD to explore this approach.

Researchers on complex diseases differ in their willingness to combine evidence over multiple samples. Lumpers point to diseases associated with ABO blood groups or HLA, where the association extends to all ethnic groups. Splitters point to malaria-dependent polymorphisms that had insufficient time to spread to all hyperendemic regions, and raise the possibility that different sets of loci produce different subtypes of disease in different populations. The number of degrees of freedom required to describe all hypothetical interactions is indefinitely large, making a Bonferroni correction of uncertain reliability and favouring Occam’s razor.

Correlations among different measures of atopy and asthma pose a problem that is both statistical and medical. How should correlated traits be assessed within and among studies? One approach has appealed to psychometricians who prefer a general factor for cognition and orthogonal specific factors. The first principal component of atopy and asthma scores may be an acceptable general factor for allergy, but the second principal component measures inflammation by giving the highest score to intrinsic asthma with bronchial hyperreactivity and the lowest score to atopy without asthma, asymptomatic individuals falling in the middle. This is attractive for genetic analysis because the two orthogonal scores are able to distinguish loci that act primarily on atopy or inflammation. A more precise estimate of susceptibility to pulmonary inflammation is unlikely to be approved by an Ethical Committee. Until candidate loci are confirmed and functionally characterised, the genetic utility of different phenotype scores and clinical definitions will remain unsettled.

Current methods for positional cloning of oligogenes have at least one serious limitation, which may be to random samples or affected pairs, quantitative traits or affection status, or like GENEHUNTER NPL they do not specify an alternative hypothesis and therefore give only an approximation to lods (Kong and Cox, 1997), or they do not distinguish maternal and paternal transmission to take advantage of sex-specific genetic maps and test for imprinting. We are now in a phase of consolidation aiming to identify and adopt the most efficient method for each situation, which must include combination of evidence over studies.

As successful methods are introduced, they encounter the problem that oligogenes have been named prematurely, without confirmation in multiple samples. Workers on insulin-dependent diabetes have named putative oligogenes IDDMn, of which only IDDM1 and IDDM2 are securely established although not precisely localised in the HLA and INS regions, respectively (Lernmark and Ott, 1998). A substantial proportion of the other loci may be type I errors. Since markers identify candidate regions, it would be prudent to withhold names for unconfirmed oligogenes. Except for the largest effects, this implies that names should not be assigned until reliable methods to assess multiple samples are adopted.

REFERENCES

Mapping oligogenes for atopy and asthma


(Received June 29, 1999)